

Message

---

**From:** Goodis, Michael [Goodis.Michael@epa.gov]  
**Sent:** 6/6/2019 6:22:14 PM  
**To:** Corbin, Mark [Corbin.Mark@epa.gov]; Echeverria, Marietta [Echeverria.Marietta@epa.gov]; Matuszko, Jan [Matuszko.Jan@epa.gov]; Kenny, Daniel [Kenny.Dan@epa.gov]; Baris, Reuben [Baris.Reuben@epa.gov]; Rosenblatt, Daniel [Rosenblatt.Dan@epa.gov]  
**CC:** Keigwin, Richard [Keigwin.Richard@epa.gov]  
**Subject:** RE: Roundup Xtend 2 Complete Potential EUP Study Locations

Thanks Mark

I will let Bayer know that we may set up a time to talk mid/late next week.

Michael L. Goodis, P.E.  
Director, Registration Division (RD)  
Office of Pesticide Programs (OPP)

Phone 703-308-8157  
Room S7623

---

**From:** Corbin, Mark  
**Sent:** Thursday, June 06, 2019 2:19 PM  
**To:** Echeverria, Marietta <Echeverria.Marietta@epa.gov>; Goodis, Michael <Goodis.Michael@epa.gov>; Matuszko, Jan <Matuszko.Jan@epa.gov>; Kenny, Daniel <Kenny.Dan@epa.gov>; Baris, Reuben <Baris.Reuben@epa.gov>; Rosenblatt, Daniel <Rosenblatt.Dan@epa.gov>  
**Cc:** Keigwin, Richard <Keigwin.Richard@epa.gov>  
**Subject:** RE: Roundup Xtend 2 Complete Potential EUP Study Locations

I think we could be able to do this next week. We are just getting our thoughts together around the submission and what data we have from the previous S3 NU submission. That and the fact that Chuck is out until Monday would say maybe middle to end of next week would be best.

Also we may want to pre-meet before any discussion with Bayer. I did catch Dan K and Reuben earlier today and we talked at length about the EUP submission and the field trials summarized in the slide set. It would be good to make sure we are all on same page before talking with Bayer

mark

---

**From:** Echeverria, Marietta  
**Sent:** Thursday, June 06, 2019 11:50 AM  
**To:** Goodis, Michael <Goodis.Michael@epa.gov>; Matuszko, Jan <Matuszko.Jan@epa.gov>; Corbin, Mark <Corbin.Mark@epa.gov>; Kenny, Daniel <Kenny.Dan@epa.gov>; Baris, Reuben <Baris.Reuben@epa.gov>; Rosenblatt, Daniel <Rosenblatt.Dan@epa.gov>  
**Cc:** Keigwin, Richard <Keigwin.Richard@epa.gov>  
**Subject:** RE: Roundup Xtend 2 Complete Potential EUP Study Locations

I defer to Mark? Mark, what do you recommend?

---

**From:** Goodis, Michael  
**Sent:** Wednesday, June 05, 2019 4:30 PM  
**To:** Echeverria, Marietta <Echeverria.Marietta@epa.gov>; Matuszko, Jan <Matuszko.Jan@epa.gov>; Corbin, Mark

<Corbin.Mark@epa.gov>; Kenny, Daniel <Kenny.Dan@epa.gov>; Baris, Reuben <Baris.Reuben@epa.gov>; Rosenblatt, Daniel <Rosenblatt.Dan@epa.gov>

Cc: Keigwin, Richard <Keigwin.Richard@epa.gov>

Subject: FW: Roundup Xtend 2 Complete Potential EUP Study Locations

Bayer's ask is to have some further discussion with us this week on the EUP and whether or not there is the possibility they can spray selected fields.

I realize we just received the application and are reviewing it, but are there some things to discuss that would be helpful?

Michael L. Goodis, P.E.  
Director, Registration Division (RD)  
Office of Pesticide Programs (OPP)

Phone 703-308-8157  
Room S7623

---

From: BHAKTA, TINA [AG/1005] <tina.bhakta@bayer.com>

Sent: Wednesday, June 05, 2019 10:03 AM

To: Keigwin, Richard <Keigwin.Richard@epa.gov>; Goodis, Michael <Goodis.Michael@epa.gov>; Echeverria, Marietta <Echeverria.Marietta@epa.gov>

Cc: MARVIN, THOMAS [AG/1920] <thomas.marvin@monsanto.com>

Subject: FW: Roundup Xtend 2 Complete Potential EUP Study Locations

Mike and Team,

I wanted to let you know that we shared two potential locations that could be repurposed for the work for our new dicamba formulation. The bottom line is that these two locations could accommodate the same study design that we have aligned with EFED on for the T&C for the Xtendimax registration in IL and MO bootheel. Because the locations are already planted there is a timing component which is reflected in the slides attached (end of June/early July target spray) for which an EUP approval would be needed.

Since the EUP scope is to conduct additional broader scope of work on product performance for 2020; would there be an opportunity to have the focus for review to be on the GLP drift vol work that that EFED would need to review as part of the section 3 registration? Just a thought for consideration?

Tom Orr has shared with Reuben and Dan this morning so we hope that we can discuss further if needed this week to assess if there is any potential for these locations to be sprayed with the new formulation in 2019. If there is any additional information that is needed please feel free to reach out or if you feel a call may be warranted as we would be happy to do that this week.

Thanks

Tina

---

From: THOMAS ORR <thomas.b.orr@monsanto.com>

Date: Wednesday, June 5, 2019 at 7:51 AM

To: "Baris, Reuben" <Baris.Reuben@epa.gov>

Cc: "Kenny, Daniel" <Kenny.Dan@epa.gov>, "BHAKTA, TINA [AG/1005]" <tina.bhakta@monsanto.com>, THOMAS MARVIN <thomas.marvin@monsanto.com>

Subject: Roundup Xtend 2 Complete Potential EUP Study Locations

Hi Reuben. As we discussed, Bayer has some fields that were planted for dicamba research this summer that could potentially be repurposed for EUP testing, pending EUP approval of course. Please see attached slide deck that provides some additional information for each of the two potential locations. Both locations could potentially accommodate the same study design that is currently being used for the XtendiMax Condition of Registration studies this season.

Tina and I would be happy to hop on a brief call later this week or early next week to discuss further if needed.

Best regards,

*Tom Orr*  
Global Regulatory Affairs Manager

////////////////

Bayer Crop Science  
Monsanto Company  
Regulatory Science  
Building FF  
Chesterfield, 63017, USA  
Tel: +1 636-737-9347  
Cell: +1 314-422-1748  
E-mail: [thomas.orr@bayer.com](mailto:thomas.orr@bayer.com)  
Web: <http://www.bayer.com>

/// Follow Bayer on:  
/// [Twitter](#) /// [Facebook](#) /// [Instagram](#) /// [LinkedIn](#) /// [YouTube](#)

The information contained in this e-mail is for the exclusive use of the intended recipient(s) and may be confidential, proprietary, and/or legally privileged. Inadvertent disclosure of this message does not constitute a waiver of any privilege. If you receive this message in error, please do not directly or indirectly use, print, copy, forward, or disclose any part of this message. Please also delete this e-mail and all copies and notify the sender. Thank you.